At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 280 enrolled
Drug / intervention
CVnCoV Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults
In Brief
A Phase 1 clinical trial evaluating CVnCoV Vaccine and Placebo for Severe Acute Respiratory Syndrome and 3 related conditions. Completed, enrolled 280 participants across 4 sites in 2 countries.
Detailed Summary
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19
CountriesBelgium, Germany
CollaboratorsCoalition for Epidemic Preparedness Innovations
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartJun 2020
First PostedJun 2020
Primary CompletionDec 2021
TodayJul 2026
First PostedJun 26, 2020
Enrollment StartJun 18, 2020
Primary CompletionDec 21, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.0 years ago
Interventions
CVnCoV Vaccinebiological
Participants will receive an intramuscular injection by needle in the deltoid area.
Placebodrug
Participants will receive an intramuscular injection by needle in the deltoid area.